PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.89

Change

+0.02 (+0.70)%

Market Cap

N/A

Volume

0.48M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+5.04 (+1.21%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

-11.65 (-1.68%)

USD 78.92B
ARGX argenx NV ADR

-19.29 (-2.92%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

-2.89 (-1.16%)

USD 30.22B
MRNA Moderna Inc

+0.30 (+0.89%)

USD 18.29B
UTHR United Therapeutics Corporatio..

-7.46 (-2.04%)

USD 15.91B
RPRX Royalty Pharma Plc

-0.20 (-0.65%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.84 (+4.62%)

USD 13.43B
INCY Incyte Corporation

-0.54 (-0.75%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.28 (+0.46%)

USD 12.74B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.03% 61% D- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.03% 61% D- 37% F
Trailing 12 Months  
Capital Gain -55.54% 30% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.54% 30% F 14% F
Trailing 5 Years  
Capital Gain -85.71% 41% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.71% 41% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -23.93% 17% F 9% A-
Dividend Return -23.93% 17% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.10% 92% A 68% D+
Risk Adjusted Return -91.69% 8% B- 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector